NCT06959706View on ClinicalTrials.gov

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions

Advanced Solid Tumors

Interventions

DRUG

TGW101

TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered separately.

Trial Locations (5)

22031

RECRUITING

NEXT Virginia, Fairfax

75039

RECRUITING

NEXT Dallas, Irving

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT San Antonio, San Antonio

85258

RECRUITING

Honor Health, Scottsdale

All Listed Sponsors

lead

Tagworks Pharmaceuticals BV

INDUSTRY